Secondary Logo

Institutional members access full text with Ovid®

Hip Arthroscopy for Femoroacetabular Impingement and Labral Tears in Patients Younger than 50 Years

Minimum Five-year Outcomes, Survivorship, and Risk Factors for Reoperations

Perets, Itay, MD; Chaharbakhshi, Edwin O., BS; Shapira, Jackob, MD; Ashberg, Lyall, MD; Mu, Brian H., BA; Domb, Benjamin G., MD

JAAOS - Journal of the American Academy of Orthopaedic Surgeons: February 15, 2019 - Volume 27 - Issue 4 - p e173–e183
doi: 10.5435/JAAOS-D-17-00258
Research Article

Introduction: There is a paucity of literature on mid-term outcomes for hip arthroscopy for femoroacetabular impingement and labral tears.

Methods: Inclusion criteria were age at surgery <50 years and documented preoperative patient-reported outcomes. Patients with a Tönnis grade >0 or previous ipsilateral hip conditions were excluded.

Results: Of 407 eligible cases, 327 hips (295 patients) had minimum 5-year follow-up. Mean age was 32.4 years. All mean patient-reported outcomes and visual analog scale improved at follow-up (P < 0.001). Mean satisfaction was 7.9. Thirty-eight hips (11.6%) required secondary arthroscopy at a mean of 25.1 months. Survivorship at minimum 5 years was 92.4%. The complication rate was 7.0%.

Conclusions: Hip arthroscopy for management of femoroacetabular impingement and labral tears in patients aged <50 demonstrates favorable and safe mid-term outcomes. Several risk factors for conversion to total hip arthroplasty in this age group warrant cautious patient selection for arthroscopy.

From the Department of Orthopaedics, Hadassah Hebrew University Hospital, Jerusalem, Israel (Dr. Perets), American Hip Institute in Chicago (Dr. Perets, Dr. Shapira, Mr. Mu, Mr. Chaharbakhshi, and Dr. Domb), Chicago, IL, and Atlantis Orthopaedics, Atlantis, FL.

Correspondence to Dr. Domb:

Dr. Domb or an immediate family member has received royalties from Arthrex, DJO Global, MAKO, Stryker, and Orthomerica; is a member of a speakers' bureau or has made paid presentations on behalf of Arthrex and Pacira Pharmaceuticals; serves as a paid consultant to Adventist Hinsdale Hospital, Amplitude, Arthrex, MAKO, Medacta, Pacira Pharmaceuticals, and Stryker; and has received research or institutional support from Arthrex, ATI, Breg, Kaufman Foundation, Medacta, Pacira Pharmaceuticals, and Stryker. None of the following authors or any immediate family member has received anything of value from or has stock or stock options held in a commercial company or institution related directly or indirectly to the subject of this article: Dr. Perets, Mr. Chaharbakhski, Dr. Shapira, Dr. Ashberg, and Mr. Mu.

© 2019 by American Academy of Orthopaedic Surgeons
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website